Program

Thursday, February 24

Keynote Session

Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA
7:00 p.m.-8:00 p.m.

Targeting the PI3K pathway in breast cancer
José Baselga, Massachusetts General Hospital, Boston, MA

Networking Reception

Friday, February 25

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: PI3K/mTOR Signaling

Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA
8:00 a.m.-10:15 a.m.

PI3-Kinase and cancer cell metabolism
Lewis C. Cantley

Direct and indirect actions of PI3K in cancer
Bart Vanhaesebroeck, Queen Mary University of London Institute of Cancer, London, England

Growth control by the mTOR pathway
David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge, MA

The TSC-mTOR pathway regulates tumor cell metabolism downstream of PI3K
Brendan D. Manning, Harvard School of Public Health, Boston, MA

* The regulation of the transcription factor SREBP by the Akt/ mTORC1 pathway and hypoxia
Caroline A. Lewis, CRUK London Research Institute, London, England

Break

Session 2: PI3K Pathway Aberrations in Human Cancer

Chairperson: Gordon B. Mills, University of Texas MD Anderson Cancer Center, Houston, TX
10:45 a.m.-1:00 p.m.

Strategies for targeting the PI3K pathway when employing combination therapies
Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA

Panning for PI3K pathway gold in the cancer genome: A tale of modern 49ers
Ramon Parsons, Columbia University, Manhasset, NY

PI3K signaling and therapeutic response in gliomas
Eric C. Holland, Memorial Sloan-Kettering Cancer Center, New York, NY

Signaling feedback upon inhibition of PI3K: Implications for clinical trials
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

* Identification of PHLPP as a tumour suppressor reveals the role of feedback compensation in PTEN-mutant prostate cancer progression and therapy
Lloyd C. Trotman, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Poster Session A / Lunch

Session 3: Development of Novel PI3K/mTOR Pathway Inhibitors

Chairperson: David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge, MA
4:00 p.m.-6:15 p.m.

Chemical genetic dissection of growth factor kinase signaling
Kevan Shokat, University of California, San Francisco, CA

The development of PI3K and mTOR inhibitors in cancer
William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA

Targeting the PI3K-mTOR pathway with cancer therapeutics: More or less
Robert T. Abraham, Pfizer Biopharmaceuticals, Pearl River, NY

GSK2126458: A potent inhibitor of PI3K and mTOR
Joel Greshock, GlaxoSmithKline, Collegeville, PA

* INK1117: A Potent and Orally Efficacious PI3Kα-selective Inhibitor for the Treatment of Cancer
Yi Liu, Intellikine, Inc., La Jolla, CA

Dinner on own / Evening off

6:15 p.m.-

Saturday, February 26

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 4: Targeting mTOR

Chairperson: Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, Houston, TX
8:00 a.m.-10:00 a.m.

Predictors and pharmacodynamic markers of rapamycin response
Funda Meric-Bernstam

Translating mTOR and translational control pathways to therapy in advanced breast cancer
Robert J. Schneider, New York University Cancer Institute, New York, NY

Pharmacology of AZD8055, a selective mTOR kinase inhibitor
Sylvie M. Guichard, AstraZeneca R&D, Macclesfield, England

Feedback regulation of PI3K-signaling pathways: Biologic and therapeutic implications
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

Break

Session 5: Late-Breaking Research / Hot Topics

Co-Chairpersons: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, and David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge, MA
10:30 a.m.-12:00 p.m.

* IKK-dependent phosphorylation and feedback inhibition of PI3K promotes nutrient deprivation-induced autophagy
William C. Comb, University of North Carolina, Chapel Hill, NC

* Identification of STAT3 as a necessary component of PI3K-mediated oncogenic transformation
Jonathan Ross Hart, The Scripps Research Institute, La Jolla, CA

* Specific amino acid substitutions in mutant KRAS differentially regulate PI3K signaling and predict patient survival and response to targeted therapy
Nathan T. Ihle, University of Texas MD Anderson Cancer Center, Houston, TX

* Proliferation in response to the PI3K/Akt pathway is suppressed by activation of p57Kip2
Devin T. Worster, Harvard Medical School, Boston, MA

* PHLPP Phosphatase Regulation of Growth Factor Receptor Signaling
Matt J. Niederst, University of California, San Diego, La Jolla, CA

* mTORC1 is an important downstream mediator of WNT signalling activation in the intestinal epithelium
William J. Faller, Beatson Institute for Cancer Research, Glasgow, Scotland

* Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K–mTOR pathway in pancreatic adenocarcinoma
Olga K. Mirzoeva, University of California, San Francisco, CA

Lunch on own / Free time

Session 6: PI3K/mTOR Signaling

Chairperson: Cheryl Lyn Walker, University of Texas MD Anderson Cancer Center, Smithville, TX
2:00 p.m.-4:00 p.m.

ATM signaling to TSC2 in the cytoplasm: The secret life of a DNA repair protein
Cheryl Lyn Walker

The phosphorylation tightrope: Balancing kinase and phosphatase activities in cancer
Alexandra Newton, University of California, San Diego, La Jolla, CA

Targeting PI3K in cancer: Mechanistic insights from genetic mouse models
Jean J. Zhao, Dana-Farber Cancer Institute, Boston, MA

Pharmacogenetic targeting of the translational machinery downstream of oncogenic mTOR signaling
Davide Ruggero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Dinner on own / Free time

Poster Session B / Reception

Sunday, February 27

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 7: Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials I

Chairperson: Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, Houston, TX
8:00 a.m.-9:30 a.m.

Molecular marker-based clinical trial designs to target the PI3K pathway
Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston, TX

Delivering on the promise of personalized molecular medicine
Gordon B. Mills, University of Texas MD Anderson Cancer Center, Houston, TX

Clinical development of MK-2206: A novel and potent oral allosteric AKT inhibitor
Li Yan, Merck & Co., North Wales, PA

Break

Session 8: Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials II

Chairperson: Funda Meric-Bernstam, UT MD Anderson Cancer Center, Houston, TX
10:00 a.m.-11:45 a.m.

Targeting the PI3K/AKT/mTOR pathway: Results from the PREDICT program
Razelle Kurzrock, University of Texas MD Anderson Cancer Center, Houston, TX

Personalized medicine strategies for PI3K inhibitors: Translating preclinical hypotheses into clinical biomarker strategies
Mark R. Lackner, Genentech, Inc., South San Francisco, CA

Clinical development of PI3K/mTOR pathway inhibitors, SAR245408 (XL147) and SAR245409 (XL765)
Joanne J. Lager, Sanofi-aventis, Cambridge, MA

* Biological effects of metformin in early stage breast cancer
Ryan J.O. Dowling, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada

Departure